| Literature DB >> 17228869 |
Scott D Kuduk1, Christina N Di Marco, Ronald K Chang, Michael R Wood, Kathy M Schirripa, June J Kim, Jenny M C Wai, Robert M DiPardo, Kathy L Murphy, Richard W Ransom, C Meacham Harrell, Duane R Reiss, Marie A Holahan, Jacquelynn Cook, J Fred Hess, Nova Sain, Mark O Urban, Cuyue Tang, Thomayant Prueksaritanont, Douglas J Pettibone, Mark G Bock.
Abstract
A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17228869 DOI： 10.1021/jm061094b
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446